BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mckenzie F, Arthur M, Ortega-loayza AG. Pyoderma Gangrenosum: What Do We Know Now? Curr Derm Rep 2018;7:147-57. [DOI: 10.1007/s13671-018-0224-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Hobbs MM, Byler R, Latour E, Bonomo L, Hennessy K, Cruz-Diaz CN, Shinohara MM, Seminario-Vidal L, Shinkai K, Ortega-Loayza AG. Treatment of pyoderma gangrenosum: A multicenter survey-based study assessing satisfaction and quality of life. Dermatol Ther 2021;34:e14736. [PMID: 33394563 DOI: 10.1111/dth.14736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Lu JD, Milakovic M, Ortega-Loayza AG, Marzano AV, Alavi A. Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. Expert Opin Investig Drugs 2020;29:1179-85. [PMID: 32880206 DOI: 10.1080/13543784.2020.1819981] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]